Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma

Inclusion Criteria: 1. Physician diagnosis of asthma confirmed objectively by airway hyperactivity to methacholine (as determined by a ≥ 20% drop in FEV at a methacholine dose of ≤ 8mg/ml after β-agonist withdrawal as per ATS guidelines) 2. Age range 18-60 years 3. FEV1 ≥ 60% predicted 4. Duration of asthma \> 6 months and on stable medication for 4 weeks 5. Prescribed and compliant with inhaled corticosteroid up to a maximum of 2000mcg beclomethasone or equivalent 6. No history of previous regular smoking and current non-smoker Exclusion Criteria: 1. Unstable asthma; defined as the presence of 1 or more of the following events in the month prior to study \[Emergency/'out of hours' visit to GP for asthma exacerbation; GP visit to patient at home for asthma exacerbation or A \& E/hospital admission for asthma exacerbation\] 2. Treatment with oral corticosteroids in the past month 3. Need for maintenance oral corticosteroid therapy 4. Pregnancy or planning to become pregnant over course of study and up to one month after 5. Excessive risk of hepatotoxicity from endothelin receptor antagonists; * Alcohol excess (defined as regular consumption above government daily recommend limits; currently defined as 28 units per wk for men, 21 units per week for women) * Previous intravenous drug use * Current or known history of liver disease (with the exception of Gilberts disease and gallstones) * Chronic hepatitis (either viral (e.g. hepatitis B or C) or autoimmune) * Bilirubin, alanine aminotransferase (ALT) or asparate aminotransferase (AST) greater than the upper limit of normal at screening 6. Anaemia (defined as haemoglobin below the lower reference range for sex) at screening 7. Renal failure (defined as eGFR less than 50 mL/minute/1.73 m2) at screening 8. Known HIV positivity 9. History of inability to tolerate bosentan or ambrisentan 10. Significant medical conditions other than asthma felt by investigator to preclude participation in study. This could be either in patients best interest or due to potential to significantly alter responses to medication and hence alter power of clinical trial (examples include; significant heart failure (NYHA grades II-IV), diabetes mellitus, bronchiectasis or haematological malignancy).